Biomax Informatics AG, the leading bioinformatics company with 20 years in the market makes an important step today towards new markets. With all its competence in knowledge management in life sciences it is now about to offer the first commercial product for brain science. NeuroXM Brain Science Suite is a unique collection of tools and features for working with multimodal high-dimensional brain data ready for clinical use.
NeuroXM Brain Science Suite is a unique collection of tools and features making the life of everyone working with multimodal brain science data from neuroimaging to genetics and transcriptomics easier. It creates a unified knowledge model containing the tremendous amount of heterogeneous data available for the brain making it easily manageable in daily clinical routines. It connects patient brain data to public knowledge in databases, atlases and ontologies for automatic annotation with methodological meta-information and becomes thereby invaluable for any clinician and scientist working with brain scans on a daily basis.
The NeuroXM suite supports every brain science task from standardizing preprocessing workflows over cataloging and sharing brain data to research driven exploration and assessments of high-dimensional brain data sets. It is further fully based on the BioXM™ Platform Technology by Biomax that has been successful at 24/7 operation of a clinical datacenter. The NeuroXM Suite, complying with the data security standards and reliability of BioXM technology, is ready to be used in clinical settings.
Customers can stay tuned on the latest developments and follow the final steps towards the launch of NeuroXM – The Biomax novel brain science product, who’s final release is set for the mid of 2018!
Biomax will be present at the bi-annual meeting of the German Biological Psychiatric Society (http://www.dgbp2018.de/) at the prestigious Psychiatric University Hospital of Heidelberg in Campus Bergheim from 14 – 16 March 2018.
Visit us at poster presentation P41 “Risk Management in First Episode Psychosis Patients” on Thursday 15 March 2018 (http://www.dgbp2018.de/dgbp2018_2.html#pos). Biomax will present results from the EU-funded research project “Neuroimaging platform for characterization of metabolic co-morbidities in psychotic disorders” (METSY) (http://www.metsy.eu/) which is one of the sources of the NeuroXM Brain Science suite idea.
NeuroXM Brain Science Suite is a unique collection of tools and features making the life of everyone working with multimodal brain science data from neuroimaging to genetics and transcriptomics easier. It creates a unified knowledge model containing the tremendous amount of heterogeneous data available for the brain making it easily manageable in daily clinical routines. It connects patient brain data to public knowledge in databases, atlases and ontologies for automatic annotation with methodological meta-information and becomes thereby invaluable for any clinician and scientist working with brain scans on a daily basis.
The NeuroXM suite supports every brain science task from standardizing preprocessing workflows over cataloging and sharing brain data to research driven exploration and assessments of high-dimensional brain data sets. It is further fully based on the BioXM™ Platform Technology by Biomax that has been successful at 24/7 operation of a clinical datacenter. The NeuroXM Suite, complying with the data security standards and reliability of BioXM technology, is ready to be used in clinical settings.
Customers can stay tuned on the latest developments and follow the final steps towards the launch of NeuroXM – The Biomax novel brain science product, who’s final release is set for the mid of 2018!
Biomax will be present at the bi-annual meeting of the German Biological Psychiatric Society (http://www.dgbp2018.de/) at the prestigious Psychiatric University Hospital of Heidelberg in Campus Bergheim from 14 – 16 March 2018.
Visit us at poster presentation P41 “Risk Management in First Episode Psychosis Patients” on Thursday 15 March 2018 (http://www.dgbp2018.de/dgbp2018_2.html#pos). Biomax will present results from the EU-funded research project “Neuroimaging platform for characterization of metabolic co-morbidities in psychotic disorders” (METSY) (http://www.metsy.eu/) which is one of the sources of the NeuroXM Brain Science suite idea.
